Volume 5, Issue 5 (May 2013)

ISSN Print: 1949-4998   ISSN Online: 1949-5005

Google-based Impact Factor: 0.86  Citations  

Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia

HTML  Download Download as PDF (Size: 179KB)  PP. 8-16  
DOI: 10.4236/health.2013.55A002    4,723 Downloads   6,751 Views  


Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects with conventional chemotherapy for newly diagnosed AML. GO is currently available only in Japan. However, several large clinical studies have demonstrated beneficial effects of GO when added to chemotherapy for AML in recent years; therefore, reconsideration of GO availability is gaining attention. Therefore, the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be positively investigated.

Share and Cite:

Tsunemine, H. and Takahashi, T. (2013) Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia. Health, 5, 8-16. doi: 10.4236/health.2013.55A002.

Cited by

No relevant information.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.